Karyopharm initiates randomized study in leukemia patients
Natick-based Karyopharm Therapeutics, a clinical-stage company that is developing treatments for cancer and other major diseases, said it has initiated a Phase-2 study of its KPT-330 compound, known as Selinexor, in patients with acute myeloid leukemia (AML).
The study is a randomized trial of Selinexor in patients aged 60 and older with relapsed AML who are not eligible for intensive chemotherapy or transplantation treatments, Karyopharm said. It will be conducted at 40 sites worldwide, including in the U.S., Canada, Europe and Israel, and include 150 patients.
Selected patients will be provided Selinexor twice a week, while others will be treated with other methods chosen by physicians. The study is expected to take about two years to complete, with overall survival rate as the primary endpoint, according to Karyopharm.
The study was designed based on results of Karyopharm’s ongoing Phase 1 study of Selinexor.
Karyopharm President and Chief Scientific Officer Sharon Shacham in a statement called the new study a “major milestone” for the company.
“We look forward to these results, and to potentially making Selinexor available to patients with this difficult to treat malignancy,” Shacham said.
WBJ Web Partners
Most Recent
Most Recent
0 Comments